About AFMD

Affimed (AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AFMD is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 97.1 M 9.705E+07 1,992 1992 0.0% 1.8062E-05 6 K 5551
UWM ProShares Ultra Russell2000 191.6 M 1.91595E+08 1,991 1991 0.0% 2.69036E-05 11 K 11109
IWC iShares Microcap ETF 831.4 M 8.31356E+08 1,383 1383 0.04% 0.0004 346 K 345574
IWM iShares Russell 2000 ETF 46.1 B 4.60786E+10 1,981 1981 0.01% 0.0001 3.1 M 3121270
IWN iShares Russell 2000 Value ETF 9.5 B 9.53317E+09 1,380 1380 0.0% 0 223 K 223354
IWO iShares Russell 2000 Growth ETF 9.4 B 9.3834E+09 1,154 1154 0.01% 0.0001 1.0 M 1037170
IWV iShares Russell 3000 ETF 9.9 B 9.87999E+09 2,886 2886 0.0% 0 75 K 75254